• About Us
  • Contact us
0
0
Book an Appointment
Home
Products
Pain Pharmacogenomic (PGx) Panel
Pain Pharmacogenomic (PGx) Panel

Pain Pharmacogenomic (PGx) Panel

Turnaround Time: 10–14 days
Genes: COMT, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4.

Overview

Our Pain Pharmacogenomic (PGx) Panel focuses on genetic variants with strong clinical evidence for their role in pain perception, opioid metabolism, NSAID response, and other pain management medications. This test provides a targeted genetic profile to help guide safe and effective pain treatment strategies.

By identifying gene–drug interactions specific to pain therapy, your healthcare provider can make more informed prescribing decisions—helping to reduce side effects, avoid treatment failure, and optimize pain relief.

$199.00

Our Mental Health PGx test analyzes your DNA to predict how you will respond to 90+ different medications used in the treatment for mental health, including but not limited to: Antidepressants, Anti-Psychotics, Anti-ADHD Agents, and Anti-Anxiety drugs, delivering a personalized medicine report unique to you.

What’s in Your Kit

  • 1 sterile cheek swabs
  • Secure collection tube
  • Detailed step-by-step instructions
  • Prepaid return shipping envelope
  • Patient consent form
  • Patient requsition form
  • Biohazard bag

Collection Instructions

Simple cheek swab (non-invasive, no needles required)

Avoid eating, drinking, smoking, or chewing gum for 30 minutes before collection

Pharmacogenics Specimen Collection Device

Let patient rinse mouth with clean water prior to the sample collection. Ensure patient does NOT eat, drink, smokeor chew tobacco, and chem gum for 30 minutes before collection specimen.

Label the outside of collection device patient’s Full Name, DOB, Date of Collection.

Open package and remove dry swab without touching sponge tip.

Place sponge tip as far back in the mouth and press firmly along the lower gums going up and down motion( against the inside of one cheek) . Use astopwatch to time the collection for at least 60 seconds per swab to collect cells. It is important to collect samples from maximum mucosal surfaces. If possible, avoid rubbing teeth.

Gently repeat step 4 on the opposite side of the cheek along the lower gums for additional 60 seconds.

Remove the swab from patient mouth and return the swab to the original specimen collection device containerand close the lid tightly.

Sample Final Report

  • Gene-by-gene analysis
  • Actionable recommendations for your provider
  • Medication list sorted by “Use as Directed,” “Use with Caution,” or “Consider Alternatives”
  • Educational notes for patients
  • Your response to hundreds of prescription medications
  • Individualized medication dosing guidelines
  • Personalized gene drug interactions

Medications and disease categories Covered

This panel evaluates genetic impact on over 23 pain-related medications, including:
  • Opioids: codeine, tramadol, hydrocodone, oxycodone, morphine, fentanyl, methadone, buprenorphine
  • NSAIDs: ibuprofen, naproxen, celecoxib, diclofenac, meloxicam
  • Muscle relaxants: tizanidine, cyclobenzaprine, baclofen
  • Other pain-related agents: topical analgesics, migraine treatments, neuropathic pain medications

Benefits Of Testing

  • Personalized pain management – Matches medication choice and dosage to your genetic profile

  • Reduce trial-and-error prescribing – Helps avoid ineffective or poorly tolerated pain medications

  • Minimize adverse drug reactions – Lowers risk of dangerous side effects, including respiratory depression from opioids

  • Lifetime relevance – Genetic results never change and can guide all future pain prescriptions

  • Faster relief – Helps identify effective medications sooner, improving quality of life

  • Better dosing precision – Guides opioid and NSAID dosing to avoid under-treatment or toxicity

Texas Diagnostics laboratories Medication Directory Filter through the list of medications and find yours
Category Therapeutic Class Generic Name Trade Name(s) Gene Evidence level
Pain Opioids Morphine MS Contin COMT Informative
Pain Muscle Relaxants Tizanidine Zanaflex CYP1A2 Informative
Pain Opioids Methadone Dolophine CYP2B6 Informative
Pain Muscle Relaxants Carisoprodol Soma CYP2C19 Informative
Pain NSAIDs Celecoxib Celebrex CYP2C9 Actionable
Pain NSAIDs Flurbiprofen Ansaid CYP2C9 Actionable
Pain NSAIDs Ibuprofen Advil, Motrin CYP2C9 Actionable
Pain NSAIDs Meloxicam Mobic CYP2C9 Actionable
Pain NSAIDs Piroxicam Feldene CYP2C9 Actionable
Pain Opioids Benzhydrocodone Apadaz CYP2D6 Actionable
Pain Opioids Codeine Codeine; Fioricet with Codeine CYP2D6 Actionable
Pain Opioids Dihydrocodeine Synalgos-DC CYP2D6 Informative
Pain Opioids Hydrocodone Vicodin CYP2D6 Actionable
Pain Opioids Oliceridine Olinvyk CYP2D6 Actionable
Pain Opioids Oxycodone Percocet, Oxycontin CYP2D6 Actionable
Pain Opioids Tramadol Ultram CYP2D6 Actionable
Pain Opioids Fentanyl Actiq OPRM1 Informative
Pain Opioids Hydrocodone Vicodin OPRM1 Informative
Pain Opioids Morphine MS Contin OPRM1 Informative
  Limitations
  • Detects only the targeted variants included in the panel; rare or novel variants will not be identified.
  • Pain response is influenced by non-genetic factors such as psychological state, comorbidities, concurrent medications, and environmental influences, which are not assessed by this test.
  • A “normal metabolizer” result does not guarantee pain relief or absence of side effects.
  • Sample quality is critical; inadequate swab collection may result in incomplete or inconclusive results.
  • Pharmacogenomic science evolves; variant interpretation may change as new evidence emerges.
No products in the cart.